These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19637953)

  • 21. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
    Szebeni J; Muggia FM; Alving CR
    J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy-related acute myeloid leukemia with 11q23 abnormality due to paclitaxel coexisting with bone marrow metastasis of breast cancer].
    Saito M; Mori A; Irie T; Tanaka M; Morioka M
    Rinsho Ketsueki; 2009 Mar; 50(3):192-6. PubMed ID: 19352087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe dermatologic reactions at multiple sites after paclitaxel administration.
    Beri R; Rosen FR; Pacini MJ; Desai SR
    Ann Pharmacother; 2004 Feb; 38(2):238-41. PubMed ID: 14742758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical properties of paclitaxel and their effects on preparation and administration.
    Trissel LA
    Pharmacotherapy; 1997; 17(5 Pt 2):133S-139S. PubMed ID: 9322880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral neuropathy in a woman with breast cancer.
    Cianfrocca M; Flatters SJ; Bennett GJ; McNicol E; Relias V; Carr D; Gillis TA
    J Pain; 2006 Jan; 7(1):2-10. PubMed ID: 16414547
    [No Abstract]   [Full Text] [Related]  

  • 26. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer.
    Cohen PR
    J Drugs Dermatol; 2009 Jan; 8(1):61-4. PubMed ID: 19180897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe necrosis due to paclitaxel extravasation.
    Herrington JD; Figueroa JA
    Pharmacotherapy; 1997; 17(1):163-5. PubMed ID: 9017777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
    Gogate US; Schwartz PA; Agharkar SN
    Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
    Mielke S; Sparreboom A; Mross K
    Eur J Cancer; 2006 Jan; 42(1):24-30. PubMed ID: 16293411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative formulations of paclitaxel.
    Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
    Choi BS; Robins HI
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):345-6. PubMed ID: 18026678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case successfully treated by desensitization for paclitaxel-associated hypersensitivity reactions].
    Yamatoya Y; Wada Y; Sato S; Morikawa T; Sakata N; Nakata J; Seki K; Wada N; Kamiyama K; Tominaga T
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):271-4. PubMed ID: 17301542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological action of paclitaxel].
    Potemski P; Płuzańska A
    Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
    Matsumura T; Imamura H; Kishimoto T; Miyazaki Y; Fujii C; Fujino M; Yasui Y; Anami S; Sumita R; Takada N; Fujita Y; Furukawa H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1565-8. PubMed ID: 19755835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skin ulceration potential of paclitaxel in a mouse skin model in vivo.
    Dorr RT; Snead K; Liddil JD
    Cancer; 1996 Jul; 78(1):152-6. PubMed ID: 8646711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy with weekly paclitaxel in breast cancer patients may increase release of cancer cells into circulation by decreasing interstitial fluid pressure.
    Altundag O; Altundag K; Gundeslioglu O; Silay YS; Ersoy Y
    Med Hypotheses; 2006; 66(4):857-8. PubMed ID: 16039067
    [No Abstract]   [Full Text] [Related]  

  • 40. Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
    D'Errico S; Baldari B; Arcangeli M; Santurro A; Frati P; Fineschi V
    Medicine (Baltimore); 2020 Oct; 99(43):e22814. PubMed ID: 33120804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.